KT621

Drug

Related News

Kymera Presents Phase 1 KT-621 Data in Japanese Adults, Notes Ongoing Phase 2b Trials

Jun 12, 2026

Kymera Therapeutics presented Phase 1 data for oral STAT6 degrader KT-621 in healthy Japanese adults, showing ≥98% STAT6 degradation and favorable safety. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing with data expected in 2027, and FDA has granted Fast Track designation for both indications.

Kymera gains FDA Fast Track for KT-621 as Gilead licenses KT-200

Apr 24, 2026

Kymera said the FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma, while Gilead licensed KT-200 and triggered a $45 million milestone payment.

Drug Hunter's Most Popular Content of 2025 Highlights Industry Trends

Dec 30, 2025

Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.